

HL161A
1 2 3
kDa
260
160
110
80
60
50
40
30
20
15
HL161B
1 2 3
kDa
260
160
110
80
60
50
40
30
20
15
10
HL161C
1 3 2
kDa
260
160
110
80
60
50
40
30
20
15
HL161D
1 3 2
kDa
260
160
110
80
60
50
40
30
20
15

FIG. 1




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 2E




FIG. 2F




FIG. 2G




FIG. 2H



HL161B
MFI
50
40
30
20
10
0
-10
0.01
0.1
1
10
100
1000
IgG Conc. (nM)
HL161A
MFI
100
80
60
40
20
0
0.01
0.1
1
10
100
1000
IgG Conc. (nM)

FIG. 3



HL161A
Blocking (%)
140
120
100
80
60
40
20
0
0.001
0.01
0.1
1
10
100
IgG Conc. (nM)
HL161B
Blocking (%)
120
100
80
60
40
20
0
0.001
0.01
0.1
1
10
100
IgG Conc. (nM)

FIG. 4



HL161A
Biotin-hIgG in serum (%)
100
10
1
0
24
48
72
96
120
144
168
192
Time (hr)
Tracer
HL161A, ip
20 mg/kg hIgG1
5 mg/kg HL161A
10 mg/kg HL161A
20 mg/kg HL161A

FIG. 5A



HL161B
Biotin-hIgG in serum (%)
100
10
1
0
24
48
72
96
120
144
168
192
Time (hr)
Tracer
HL161B, ip
20 mg/kg hIgG1
5 mg/kg HL161B
10 mg/kg HL161B
20 mg/kg HL161B

FIG. 5B



Vehicle
HL161A 5mpk
HL161A 20mpk
HL161B 5mpk
HL161B 20mpk
* P<0.05 vs. Vehicle
** P<0.01 vs. Vehicle
IgG in serum (%predose)
Days after the first dose

FIG. 6A



HL161A_5mpk
HL161B_5mpk
IgG in serum (% predose)
140
120
100
80
60
40
20
0
-2 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
Days after the first dose

FIG. 6B



HL161A_20mpk
HL161B_20mpk
IgG in serum (% predose)
140
120
100
80
60
40
20
0
-2 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
Days after the first dose

FIG. 6C



HL161A
20 mg/kg
5 mg/kg
HL161A (ug/mL)
1000.0
100.0
10.0
1.0
0.1
0
5
10
15
Time (day)

FIG. 7A



HL161B
20 mg/kg
5 mg/kg
HL161B (ug/mL)
1000.0
100.0
10.0
1.0
0.1
0
5
10
15
Time (day)

FIG. 7B



IgM in serum (%predose)
160
140
120
100
80
60
40
20
0
-2
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
Days after the first dose
Vehicle
HL161A 5mpk
HL161A 20mpk
HL161B 5mpk
HL161B 20mpk

FIG. 8A



IgA in serum (%predose)
160
140
120
100
80
60
40
20
0
-2
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
Days after the first dose
Vehicle
HL161A 5mpk
HL161A 20mpk
HL161B 5mpk
HL161B 20mpk

FIG. 8B



Albumin in serum (%predose)
160
140
120
100
80
60
40
20
0
-2
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
Days after the first dose
Vehicle
HL161A 5mpk
HL161A 20mpk
HL161B 5mpk
HL161B 20mpk

FIG. 8C



Screening
Open-Label treatment
12 Week Follow Up
Screening
RVT-1401
680 mg x 2 weeks + 340 mg x 4 weeks
N=8
Week -3 to -6
Wk 1
Day 3
Day 5
Wk 2
Wk 3
Wk 4
Wk 5
Wk 6
Day 38
Day 40
Wk 7
Wk 8
Wk 9
Wk 10
Wk 12
Wk 14
Wk 16
Wk 18

FIG. 9



Screening
Double-blind treatment
8 Week F/U
Screening
RVT-1401 680 mg/week N=22
RVT-1401 340 mg/week N=22
RVT-1401 255 mg/week N=11
Placebo N=22
Wk -3 to -6
Wk 1
Wk 2
Wk 3
Wk 4
Wk 5
Wk 6
Wk 7
Wk 8
Wk 9
Wk 10
Wk 11
Wk 12
Wk 13
Wk 14
Wk 16
Wk 20

FIG. 10